MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1038/bjc.2015.377

Медицинская библиотека · British journal of cancer · 2015

Reproductive factors and epithelial ovarian cancer survival in the EPIC cohort study.

Bešević Jelena, Gunter Marc J, Fortner Renée T, Tsilidis Konstantinos K, Weiderpass Elisabete, Onland-Moret N Charlotte, Dossus Laure, Tjønneland Anne, Hansen Louise, Overvad Kim, Mesrine Sylvie, Baglietto Laura, Clavel-Chapelon Françoise, Kaaks Rudolf, Aleksandrova Krasimira, Boeing Heiner, Trichopoulou Antonia, Lagiou Pagona, Bamia Christina, Masala Giovanna, Agnoli Claudia, Tumino Rosario, Ricceri Fulvio, Panico Salvatore, Bueno-de-Mesquita H Bas, Peeters Petra H, Jareid Mie, Quirós J Ramón, Duell Eric J, Sánchez María-José, Larrañaga Nerea, Chirlaque María-Dolores, Barricarte Aurelio, Dias Joana A, Sonestedt Emily, Idahl Annika, Lundin Eva, Wareham Nicholas J, Khaw Kay-Tee, Travis Ruth C, Rinaldi Sabina, Romieu Isabelle, Riboli Elio, Merritt Melissa A

СтатьяПоддержка исследования: вне правительства СШАПеревод в очереди

Аннотация

BACKGROUND

Reproductive factors influence the risk of developing epithelial ovarian cancer (EOC), but little is known about their association with survival. We tested whether prediagnostic reproductive factors influenced EOC-specific survival among 1025 invasive EOC cases identified in the European Prospective Investigation into Cancer and Nutrition (EPIC) study, which included 521,330 total participants (approximately 370,000 women) aged 25-70 years at recruitment from 1992 to 2000.

METHODS

Information on reproductive characteristics was collected at recruitment. Cox proportional hazards regression models were used to estimate hazard ratios (HRs) and 95% confidence intervals (CIs), and multivariable models were adjusted for age and year of diagnosis, body mass index, tumour stage, smoking status and stratified by study centre.

RESULTS

After a mean follow-up of 3.6 years (±3.2 s.d.) following EOC diagnosis, 511 (49.9%) of the 1025 women died from EOC. We observed a suggestive survival advantage in menopausal hormone therapy (MHT) users (ever vs never use, HR=0.80, 95% CI=0.62-1.03) and a significant survival benefit in long-term MHT users (⩾5 years use vs never use, HR=0.70, 95% CI=0.50-0.99, P(trend)=0.04). We observed similar results for MHT use when restricting to serous cases. Other reproductive factors, including parity, breastfeeding, oral contraceptive use and age at menarche or menopause, were not associated with EOC-specific mortality risk.

CONCLUSIONS

Further studies are warranted to investigate the possible improvement in EOC survival in MHT users.

Для цитирования: Bešević Jelena, Gunter Marc J, Fortner Renée T, Tsilidis Konstantinos K, Weiderpass Elisabete, Onland-Moret N Charlotte, Dossus Laure, Tjønneland Anne, Hansen Louise, Overvad Kim, Mesrine Sylvie, Baglietto Laura, Clavel-Chapelon Françoise, Kaaks Rudolf, Aleksandrova Krasimira, Boeing Heiner, Trichopoulou Antonia, Lagiou Pagona, Bamia Christina, Masala Giovanna, Agnoli Claudia, Tumino Rosario, Ricceri Fulvio, Panico Salvatore, Bueno-de-Mesquita H Bas, Peeters Petra H, Jareid Mie, Quirós J Ramón, Duell Eric J, Sánchez María-José, Larrañaga Nerea, Chirlaque María-Dolores, Barricarte Aurelio, Dias Joana A, Sonestedt Emily, Idahl Annika, Lundin Eva, Wareham Nicholas J, Khaw Kay-Tee, Travis Ruth C, Rinaldi Sabina, Romieu Isabelle, Riboli Elio, Merritt Melissa A. Reproductive factors and epithelial ovarian cancer survival in the EPIC cohort study.. British journal of cancer. 2015. DOI: 10.1038/bjc.2015.377.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.